Personalisation the Management of Inflammatory Diseases
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmacokinetics and Pharmacodynamics".
Deadline for manuscript submissions: closed (15 July 2023) | Viewed by 25339
Special Issue Editors
Interests: analytical method development; pharmacokinetics; therapeutic drug monitoring; toxicology
Special Issues, Collections and Topics in MDPI journals
Interests: perinatal pharmacology; paediatric pharmacology; pharmacometrics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In inflammatory diseases (ID) such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), pharmacotherapy should be personalized. ID treatment is complex, with highly different treatment modalities ranging from small-molecular anti-inflammatory drugs and corticosteroids to important developments such as monoclonal antibodies (mAbs). In the case of mAbs, an extra dimension is caused by the production of anti-drug antibodies, complicating the choice and dose of the drug. Evidence is emerging that drug choice and especially drug dosing should be personalized and target concentration is driven. Detailed pharmacological knowledge including pharmacogenetics, pharmacodynamics and concentration-effect relationships is essential for choosing the right drug, in the right dose, in the right administration form, at the right time, for each individual patient. We are pleased to invite you to make a contribution to this Special Issue that is devoted to the personalization of inflammatory disease management.
This Special Issue aims to give an overview of the clinical pharmacodynamic and pharmacokinetic considerations needed for tailoring treatment with the most common anti-inflammatory drugs for various classes of inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Special interest is for the treatment of women with inflammatory diseases of reproductive age and for the emergence of concentration-targeted therapy using therapeutic drug monitoring in inflammatory diseases.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: clinical pharmacodynamics and pharmacokinetics of non-steroid and non-antibody classes of anti-inflammatory drugs, clinical pharmacodynamics and pharmacokinetics of monoclonal antibody anti-inflammatory drugs and the role of anti-drug antibodies, the role of therapeutic drug monitoring in inflammatory diseases, treatment of pregnant women with inflammatory diseases, treatment of inflammatory diseases in lactating women, treatment of children with inflammatory diseases.
We look forward to receiving your contributions.
Prof. Dr. Daniel J. Touw
Dr. Paola Mian
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- inflammation
- monoclonal antibody
- therapeutic drug monitoring
- anti-drug antibody
- anti-inflammatory drugs
- thiopurines
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.